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Abstract
Background: Solitary splenic metastases are a rare occurrence, and the nasopharyngeal carcinoma represents
one of the most uncommon primary sources. The present study aimed to describe a rare case of a solitary single
splenic metastasis from nasopharyngeal carcinoma and to assess the number of cases of isolated nasopharyngeal
carcinoma metastases to the spleen reported in the literature.
Main body: We describe the case of a 56-year-old man with a history of nasopharyngeal carcinoma and complete
remission after chemo-radiotherapy. Three months after complete remission, positron emission tomography/
computed tomography scan revealed a hypermetabolic splenic lesion without increased metabolic activity in
other areas. After laparoscopic splenectomy, the pathology report confirmed a single splenic metastasis from
undifferentiated carcinoma of the nasopharyngeal type. The postoperative period was uneventful. We also
performed a systematic review of the literature using MEDLINE and Google Scholar databases. All articles reporting
cases of splenic metastases from nasopharyngeal carcinoma, with or without histologic confirmation, were
evaluated. The literature search yielded 15 relevant articles, which were very heterogeneous in their aims and
methods and described only 25 cases of splenic metastases from nasopharyngeal carcinoma.
Conclusion: The present review shows that solitary splenic metastases from nasopharyngeal carcinoma are a rare
event, but it should be considered in patients presenting with splenic lesions at imaging and a history of primary
or recurrent nasopharyngeal carcinoma. No evidence supports a negative impact of splenectomy in patients with
solitary splenic metastasis from nasopharyngeal carcinoma.
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Background
Splenic metastases from non-hematologic malignancies
are rare [1–4], but according to several studies, they can
occur in cases of disseminated disease [5–7]. Their
prevalence ranges from 0.6 % [3] to 7.1 % [8] in autopsy
series of patients with cancer and from 1.1 % [3] to
3.4 % [9] in a series of patients who have undergone
splenectomy.
The most frequent primary sources of splenic metasta-
ses from non-hematologic malignancies are breast, lung,
ovarian, colorectal, and gastric adenocarcinomas, along
with skin melanoma [3, 8, 10, 11]. By 2007, only 93 well-
documented cases of solitary splenic metastases were
reported [1], with colorectal and ovarian cancer being
the most common sources and breast and skin melano-
mas the most uncommon [1, 12–15].
Among the uncommon primary sources of splenic me-
tastases, there is the nasopharyngeal carcinoma (NPC)
[3]. This type of tumor is sporadic in western countries
(incidence: 0.5–2/100.000/year) and more frequent in cer-
tain endemic areas, such as southern China (incidence:
25/100.000/year, Hong Kong) [16, 17]. Intermediate-risk
regions are the Middle East, southeastern Asia, northern
Africa, and Alaska. NPC is usually unresectable at
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diagnosis, but it is more responsive to chemotherapy and
radiotherapy than other cancers of the head and neck
[18]. However, NPC is prone to early metastatic spread.
Cervical lymph node metastases are present at diagnosis
in 75–90 % of cases and are bilateral in more than 50 % of
the cases [19–21]. A cervical lymph node advanced
disease is linked to a higher risk of distant metastasis
(33 % for N1, 70 % for N2/N3 at 10 years) and reduced
survival. Distant metastases are present at diagnosis in
5–11 % of patients, and the most common sites are
bone, lung and liver tissues. According to the 7th
edition of the American Joint Committee Cancer
Staging Manual [22], the 5-year survival rates by stage
of NPC are 72 % for stage I, 64 % for stage II, 62 % for
stage III, and 38 % for stage IV.
In the present study, we report the case of a patient
with a complete remission (CR) of a NPC after chemo-
radiotherapy, who underwent splenectomy for a solitary
hypermetabolic splenic lesion detected at the 3-month
follow-up. Additionally, we performed a systematic
review of the literature with the aim of assessing the
number and characteristics of the reported cases of
splenic metastases from NCP.
Case report
A 56-year-old Caucasian man, smoker, underwent an
ENT examination for enlarged left cervical lymph node
associated with left otalgia appearing 3 months earlier.
At nasal endoscopy, a nasopharyngeal lesion extending
from the left Rosenmüller fossa to the choanae was
found, and biopsies were performed. The pathology
report was conclusive for undifferentiated carcinoma of
the nasopharyngeal type (UCNT). The cervical contrast-
enhanced computed tomography (CT) showed enlarged
jugular nodes bilaterally (largest sizes were 25 × 22 mm
and 23 × 18 mm on the left side) with left jugular vein
compression and signs of nodal necrosis. The thoracic
scan detected an irregular nodule of 6 mm in the
medial-basal segment of the right lung and non-specific
micro-nodules in the left superior lobe. The abdominal
scan showed no liver focal lesions or other organ in-
volvement. A magnetic resonance imaging (MRI) was
performed to assess more accurately the loco-regional
extent of the tumor. It showed no intracranial extension
and confirmed a skull base erosion (left basisphenoid
inferior lysis) with thickening of the nasal fossae soft
tissues (8 mm) at the level of the choanae. Cervical
lymph node disease was confirmed at the IIB level on
the right side and at the IB, II, III, and IV levels on the
left side. A subsequent positron emission tomography
(PET)/CT scan showed a high standardized uptake value
(SUV) in the nasopharynx with involvement of the
sphenoidal sinus and left greater wing. Serological tests
for EBV were positive. The patient was classified as stage
IVA (T4N2cM0) and treated with neoadjuvant chemo-
therapy followed by intensity modulated radiation radio-
therapy (IMRT) and chemotherapy. The neoadjuvant
chemotherapy consisted of 3 cycles of docetaxel, carbo-
platin and 5-fluorouracil, which were followed by IMRT
(70 Gy on the nasopharynx and involved lymph nodes
and prophylactic treatment with 56 Gy on the other
nodal areas) and two cycles of cisplatin. A complete
remission was obtained, with no evidence of disease on
CT scan at the end of the treatment.
However, at 3 months from the end of treatment, the
follow-up PET/CT scan detected a hypermetabolic
nodule of the spleen (size: 24 × 17 mm) with SUV of 7.
No other areas showed increased metabolic activity
(Fig. 1). A biopsy of the splenic nodule was impossible
to perform because of the nodule location and an incipi-
ent severe ischemic heart disease. The patient needed to
be hospitalized and underwent coronary angioplasty and
stenting. At 6 months, another PET/CT scan revealed
increased size (33 × 26 mm) and metabolic activity
(SUV 14) of the spleen nodule, without other suspi-
cious lesions. The CT performed at 9 months con-
firmed that the pulmonary nodules had completely
disappeared. No abdominal symptoms were observed.
Fig. 1 Imaging. After 3 months of complete remission following chemo-radiotherapy, a whole-body FDG-PET showed a splenic focal lesion with
increased uptake
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In accordance with the decision of a multidisciplinary
team, the patient underwent standard laparoscopic
splenectomy at both diagnostic and therapeutic aims.
The patient was positioned in a semi-lateral right
decubitus position with a cushion placed under the right
flank. Four ports were used. First, a 12-mm peri-
umbilical optical port was placed with the Hasson
technique [23, 24]. Then, the other three ports were
visualized directly, and their locations were as follows:
an epigastric 5-mm port slightly to the left of the median
line, a 12-mm port, and another 5-mm port 4 cm below
the left costal arch on anterior and middle axillary lines.
A 30° laparoscope and bipolar radiofrequency device
were used. The spleno-colic ligament was dissected to
expose the lower pole of the spleen, and the gastro-
splenic ligament was dissected to expose the splenic
hilum. Careful dissection of the splenic artery and vein
was performed. The hilar vessels were separated using a
30-mm vascular stapler, with the artery identified first.
The diaphragmatic and posterior attachments of the
spleen were then dissected, and the entire organ was re-
moved through a Pfannenstiel incision. The operating
time was 120 min.
The specimen weighed 236 g and measured 10.5 ×
10.5 × 4.5 cm. The pathology report described a 38 × 35-
mm sized single splenic nodule, which was well-delimited
and homogeneous with morphological and immunophe-
notypical features consistent with a metastasis from
UCNT (Figs. 2 and 3). An abdominal CT scan performed
6 days after the operation showed multiple thrombosis of
the splenic vein and both right and left portal branches.
Anticoagulation therapy was started. The patient was
discharged 10 days after splenectomy. At 4 months of
follow-up, the patient showed resolution of splenic and
portal thrombosis and no evidence of recurrence. After
discussion in a multidisciplinary meeting, no adjuvant
treatments were performed.
Systematic review of the literature
Materials and methods
The methodological approach included the development
of the selection criteria, definition of the search strategy,
assessment of the study quality, and abstraction of the
relevant data. The PRISMA statement checklist for
reporting a systematic review was applied [25].
Study inclusion criteria
The study selection criteria were defined before starting
the data collection to allow proper identification of the
studies eligible for the analysis. All studies reporting
distant metastasis from nasopharyngeal carcinoma or
splenic metastases from different primary tumors were
retrieved and checked for eligibility. The selection
criteria included the following:
– Types of study: all types of original articles
(including case report) with no limit of time.
– Types of participants: patients affected by NPC
with splenic metastases detected by biopsy,
imaging, or autopsy.
Literature search strategy
A literature search was performed with the following on-
line databases: MEDLINE (through PubMed) and Google
Scholar. A specific research equation was formulated
using the following keywords and/or MeSH terms: spleen,
Fig. 2 The pathologic specimen. The spleen weighed 236 g and measured 10.5 × 10.5 × 4.5 cm. The metastasis appeared as a gray, well-delimited,
homogeneous, single nodule that was 38 × 35 mm in size and with 10 % of the section surface occupied by necrotic areas
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metastasis, splenic metastasis, splenic neoplasms, naso-
pharyngeal, and nasopharyngeal neoplasms. In addition,
reference lists from eligible studies and relevant review
articles were crosschecked to identify additional studies.
No time limitation was applied. Studies written in English,
French, or Italian, and meeting the selection criteria were
reviewed.
Study selection and quality assessment
The titles and abstracts of the retrieved studies were
screened for relevance by two independent reviewers
(PG, FB). Subsequently, a full-text analysis of the
selected articles was carried out. Any disagreement
between the two reviewers during the study selection
process was resolved by discussion with a third reviewer
(NdeA). The Grading of Recommendations Assessment
Development and Evaluation (GRADE) system was used
to grade the “body of evidence” emerging from this
review [26].
Data extraction
All studies reporting cases of splenic metastasis from
nasopharyngeal cancer were retrieved and included in
this systematic review.
Results
Literature search and selection
The preliminary literature search identified 682 articles.
Of these, 655 articles were rejected because they were
not pertinent to the review questions or duplicates,
whereas 27 were retained after screening their titles and
abstracts. At the full-text examination, 15 studies were
selected. The manual search and the crosscheck of the
reference lists did not yield other relevant articles. A
flow chart illustrating the study identification and inclu-
sion/exclusion processes is shown in Fig. 4.
Study characteristics
Among the 15 selected studies [3, 5, 27–39] reporting
on splenic metastases from NPC, 13 were published
between 2000 and 2015, one was published in 1989,
and one was published in 1952. The included studies
were very heterogeneous in their design, aims and
methods. There were three case reports [27, 36, 38]
and 12 case series [3, 5, 28-35, 37, 39]. The studies
focused on NPC and the imaging techniques used for
diagnosis (n = 5) [28, 33, 35, 37, 39], splenic metasta-
ses from solid tumors (n = 3) [3, 5, 31], experience of
a single institution in NPC treatment (n = 2) [30, 34],
use of serum markers in monitoring NPC systemic
relapse (n = 1) [29], and chemotherapy in NPC patients
(n = 1) [32]. Nine studies [3, 28, 29, 32–35, 38, 39] were
performed in Asian populations, three in Western
countries [5, 31, 37], one in the Middle East [27], one
in Africa [30], and one in India [36]. Overall, 25 cases
of splenic metastases from NPC were described.
In seven case series, the included patients had a diag-
nosis of primary NPC [28–30, 32–35]. In two of these
studies, distant metastases were identified [28, 30]. In
other four series [3, 5, 31, 37], the included patients
had a diagnosis of splenic metastases; while splenic
focal lesions were identified at imaging in another study
[39]. Most cases of splenic metastases (n = 15) were
detected by imaging techniques (US, CT, MRI, and
PET/CT). In two cases [29, 31], the detection method
was not clearly reported. Three cases were found at
autopsy [5]. Another five cases were reported in a study
that combined data from autopsy and splenectomy [3].
The histological confirmation of NPC metastases to
the spleen was reported in only eight cases. For the
other cases (n = 17), the NPC origin was reported ac-
cording to the history of the primary tumor and imaging
(Tables 1 and 2).
Fig. 3 The pathologic specimen. The spleen weighed 236 g and measured 10.5 × 10.5 × 4.5 cm. The metastasis appeared as a gray, well-delimited,
homogeneous, single nodule that was 38 × 35 mm in size and with 10 % of the section surface occupied by necrotic areas
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Solitary splenic metastases with histological confirm-
ation were reported in three cases only [3, 27, 38]
(Table 1). In particular, the case reported by Suh et al.
[38] had a presentation similar to our patient. Indeed,
the authors described the case of a young male patient
with a history of NPC who had a disease-free survival
for 7 months after surgery and chemoradiation therapy.
The patient was asymptomatic when a hypermetabolic
splenic lesion was detected at the PET/CT scan. A per-
cutaneous biopsy confirmed the metastatic involvement
of the spleen and a laparoscopic splenectomy was per-
formed. No recurrence was observed after 5 months of
follow-up. Similarly, Abu-Zaid et al. [27] reported the
case of a young man with a history of NPC who experi-
enced referred pain in the upper abdominal quadrant. A
splenic lesion was detected by means of a CT scan, and
an ultrasound-guided biopsy confirmed a NPC metasta-
sis. In all cases, the confirmatory histology showed an
UCNT type of NPC solitary splenic metastasis, and all
patients underwent successful splenectomy. No study re-
ported relapse or recurrence after the treatment of
splenic metastasis.
Prevalence of NPC metastases to the spleen
The overall number of patients analyzed in the studies
selected for this systematic review was 2409, including
1212 patients with a diagnosis of NPC [27–30, 32–36, 38]
and 1197 patients with a diagnosis of splenic metastases
from several primary tumors or splenic focal lesions
[28, 33, 35, 37, 39]. Of the 1212 patients with a diagno-
sis of NPC, 417 had also distant metastases. Splenic
metastases were detected in 1.07 % of all NPC patients
(13/1212) and in 1.19 % of patients with NPC and dis-
tant metastases (5/417). Moreover, NPC represented
1 % of the primary sources among patients with a
diagnosis of splenic metastases secondary to all solid
tumors (12/1197).
Study quality assessment
Two reviewers (PG and FB) scored the methodological
qualities of the included studies according to the criteria
described above. No RCT was found. The studies were
case reports or case series with different methods and
aims. The GRADE system was used to enable a consist-
ent judgment of the quality of the available evidence
Fig. 4 Flow chart of the search, selection, and inclusion processes for the systematic review of the literature. An example PubMed search equation:
((“spleen”[MeSH Terms] or “spleen”[all fields] or “splenic neoplasms”[MeSH terms] or “splenic metastasis”[all fields]) and (“neoplasm metastasis”[MeSH
Terms] or (“neoplasm”[all fields] and “metastasis”[all fields]) or “neoplasm metastasis”[all fields] or “metastasis”[all fields])) and (“nasopharynx”[MeSH
terms] or “nasopharyngeal neoplasms”[MeSH terms] or “nasopharynx”[all fields] or “nasopharyngeal”[all fields])
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Table 2 Summary of the studies reporting on non-solitary (or not specified) splenic metastases from NPC










1952 Abrams et al. [5] CS 1000 patients with splenic
metastases from carcinomas
3 (0.3 %) Autopsy NS NS NS
1989 Siniluoto et al. [37] CS 31 patients with splenic
metastases
1 (3.2 %) US NS NS NS
2000 Wan et al. [39] CS 53 patients with focal splenic
lesions
2 (3.7 %) US NS NS NS
2000 Lam & Tang [3] CS 92 patients with splenic
metastases
4 (4.3 %) NS NS UCNT NS
2001 Gacani et al. [30] CS 65 patients with NPC and DM 1 (1.5 %) US NS NS DM within 24 months
after therapy
2004 Cho et al. [29] CS 31 patients with recurrent
type 2 NPC
1 (3.2 %) NS NS NS NS
2010 Radhakrishnan
et al. [36]
CR 1 pediatric patient with
UCNT
1 FDG-PET/CT NS NS Death after 90 days of
chemotherapy
2010 Ng et al. [35] CS 179 NPC patients at high
risk of residual disease or
with suspected recurrence
1 (0.5 %) WB-MRI and
FDG-PET/CT
NS NS NS
2011 Gatenby et al. [31] CS 21 patients undergone
splenectomies for DM
1 (4.7 %) NS Primary tumor, radical
neck dissection and
synchronous splenectomy
SCC DFS: 1 year 10 month
OS: 2 years 3 months
2013 Hsieh et al. [32] CS 22 patients with
non-keratinizing or
undifferentiated NPC
1 (4.6 %) US, CT or MRI NS NS Median time to PD:
10 months;
Median OS: 16 months
2015 Mak et al. [34] CS 558 patients with NPC 1 (0.2 %) CT and PET/CT NS NS 10.8–18.4 months before DF;
Mean DSS in patients with DM:
31.2 months (95 % CI 20.9–41.6)
Mean OS in patients with
DM: 28.2 months
(95 % CI 19.3–37.1)
2015 Ma et al. [33] CS 2 pediatric patients
with NPC
1 FDG-PET/CT NS NS NS
2015 Al Tamimi et al. [28] CS 352 patients with NPC
and DM
4 (1.1 %) FDG-PET/CT NS NS NS
CR case report, CS case series, NPC nasopharyngeal carcinoma, UCNT undifferentiated carcinoma of the nasopharyngeal type, SCC squamous cell carcinoma, DM distant metastases, NS not specified, CT computed tomography,














included in this systematic review, and the studies
retrieved were judged as having evidence of very low
quality. Of note, the majority of the studies were retro-
spective, which, by definition, are susceptible to major
selection bias, as well as misclassification, detection, or
information bias due to the unknown accuracy of record
keeping [40]. Moreover, other specific sources of bias
(e.g., attrition and reporting bias) cannot be ruled out.
The heterogeneous features of the studies evaluated, the
low number of pertinent articles found and the lack of
specific studies in the literature restrict the possibility of
large remarks and represent the main limitations of the
present systematic review.
Discussion
The present study describes a rare case of a patient who
underwent splenectomy for a solitary splenic metastasis
from UCNT. Moreover, the systematic review found 25
cases of splenic metastases from NPC reported in the
literature, with solitary metastases reported in only three
of these cases. Based on the available literature, the
estimated rate of metastases to the spleen in patients
with a diagnosis of NPC is approximately 1 %. Moreover,
NPC represents the 1 % of all sources of spleen metasta-
ses among metastatic solid cancers.
The very low number of splenic metastases from NPC
reported in the literature defines this event as rare. The
most recent study on this topic was published in 2007
and reported 93 well-documented cases of solitary
splenic metastases [1]. The primary source was a gyne-
cologic cancer in 29 % of these cases (19 % ovarian and
7 % endometrial) and colorectal cancer in 21 %. Several
other primary sites, such as the lung, esophagus, stom-
ach, kidney, breast, prostate and skin, were described,
but no case of metastases from NPC was reported.
In most of the cases, splenic metastases are diagnosed
incidentally in asymptomatic patients. However, splenic
metastases, especially the isolated ones, may also occur
in association with non-specific clinical manifestations,
such as fatigue, weight loss and fever; anemia or
thrombocytopenia caused by hypersplenism; pain in the
left upper abdominal quadrant; splenomegaly or spon-
taneous splenic rupture [3, 10, 14, 41–45]. Symptomatic
lesions are more frequently reported in women and in
younger patients, and the mean maximum size of the le-
sions in these patients is usually larger than in asymp-
tomatic patients [3]. Moreover, the presence of splenic
metastatic foci might also be associated with an increase
in serum tumor markers, which might precede the
imaging detection of splenic lesions by years [9].
Several authors reported that the increased use of
imaging and PET scan, the close follow-up and the
prolonged survival favored an increasing detection of
metastases to the spleen [1, 9, 46]. Most often, splenic
metastases are diagnosed by means of ultrasonography
or CT, but MRI can also be used to study splenic focal
lesions [9]. However, the differentiation between benign
and malignant splenic focal lesions can be difficult using
these techniques, and an 18F-FDG scan is often per-
formed [1, 9, 46]. A positive history of cancer appeared as
the only independent predictive factor for malignancy of a
splenic lesion [9], and this is consistent with our case re-
port and with the current literature [3, 10, 14, 41–45]
Generally, in patients with a history of malignancy, a
solitary splenic lesion should be first considered as a
metastases [10]. In these patients, a histologic diagnosis
should be achieved by percutaneous biopsy or splenec-
tomy [1, 47–49]. According to several studies, imaging-
guided percutaneous biopsy of suspicious splenic lesions
is relatively safe and accurate [9, 11], with a diagnostic
yield and accuracy of 90–92 and 95 %, respectively, in
front of a 2 % rate of major complications [1, 9]. How-
ever, splenectomy is much more common in clinical
practice, mainly because of the hemorrhagic risk [1],
showing a diagnostic yield of 95 % and representing at
the same time a therapeutic procedure [11]. Splenec-
tomy has been reported for both synchronous or meta-
chronous metastases [31, 48–51], and some authors
considered the surgical treatment of isolated splenic
metachronous metastases as effective as for hepatic and
pulmonary secondary lesions in the control of the
neoplastic disease [2, 48, 51–53]. However, splenectomy
for solitary metastases also represents a therapeutic
challenge because of its uncertain impact on the
patient’s prognosis. Indeed, splenic involvement is
generally linked to a widespread disease [7, 48], and a
survival inferior than 30 days was reported in case of
infarction in a metastatic spleen [54].
To assess the role of surgery in the treatment of
isolated splenic metastases, Piardi et al. [48] reported 28
cases of splenectomy for isolated metastases to the
spleen, which in most cases involved single lesions. No
increase complication rate or mortality was reported,
with a disease-free and an overall survival rates ranging
between 3 and 31 months and between 3 and 96 months,
respectively. The authors concluded that, although
prognosis is always linked to the primary tumor stage,
splenectomy can be justified because it might avoid
complications related to a progressive increase in the
metastatic volume and an infiltrative spread involving
surrounding organs and tissues, especially diaphragm,
and abscess formation [10, 55]. Furthermore, splenec-
tomy could also be justified as a debulking procedure
before chemotherapy [55–57], it could result in longer
survival [51, 57], and it should be performed shortly
after the detection of the splenic metastasis [57].
Both laparoscopic and open splenectomy can be
performed. When operating for malignancies, the open
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approach is usually preferred because it could provide
an easier access to other areas if needed [31]. However,
several studies considered laparoscopic splenectomy a
highly reliable procedure that can be performed safely
[58]. In our case report, the lesion was well-delimited
with no invasion of surrounding tissues, and no difficul-
ties were encountered in performing a laparoscopic
splenectomy.
To date, it is difficult to predict the clinical behavior of
solitary splenic metastases because its occurrence is rare,
and the literature on this topic contains mostly case re-
ports with short follow-up periods. Cancer cells already
implanted in the splenic parenchyma might not be de-
tected at the time of primary diagnosis by conventional
methods, and the hostile splenic environment might not
facilitate the growth of micrometastatic foci. This might
explain the contrast between the prevalence of splenic
micro-metastases at autopsy in patients with multivisc-
eral cancer and the rarity of clinically detectable lesions.
Therefore, splenic metastases might result from the
growth of early blood-borne disseminated cancer cells
within the spleen after a certain period of clinical latency
[1, 10], which sometimes is very long (up to 7 [3] or
11 years [59]). This might also explain the long-term re-
mission achieved in some patients treated with splenec-
tomy alone [3, 10, 13, 48, 57] supporting that isolated
splenic metastases are not necessarily the precursor sign
of active metastatic cancer in the terminal stage.
The anatomic extent of the metastasis is closely associ-
ated with the prognosis of the patients with metastatic
NPC [60]. A single metastatic lesion in an isolated
location (organ or site) is reported to be associated with
prolonged survival compared to multiple metastatic
lesions in a single or multiple locations [61, 62]. A grow-
ing body of evidence shows that long-term survival
could be achieved for selective NPC patients with lim-
ited metastatic lesions by a combination of systemic and
local therapies [63, 64]. The reported overall survival of
NPC patients after the detection of distant metastases
ranged from 22 to 120 months [60, 61, 65]. Furthermore,
the distant failure hazard is estimated to decrease by
19 % for each year the latency [66].
The great heterogeneity encountered in the studies
analyzed in the present systematic review, particularly
the different study designs, aims and methods, repre-
sents the main limitation of the present study. Most of
the studies were published between 2000 and 2015,
although two were dated in the 1980s and 1950s. This
very large time frame may also impact on the heterogen-
eity of diagnostic and therapeutic protocols changed and
improved over the years. Important data, such as
survival rates, were not always specific for NPC cases of
splenic metastases. Autopsy series hamper the possibility
to remark on the clinical aspects and prognosis.
However, despite these limitations mainly inherent in
the currently available studies, the present study is the
first one to systematically review the literature on splenic
metastases from NPC, and it can be useful to build a
general framework regarding splenic metastases, thus
providing useful information to guide clinical practice.
Further and more specific studies are needed to better
assess the incidence of splenic involvement in patients
with NPC, and to evaluate the impact of splenectomy in
cases of metastases to the spleen.
Conclusions
According to the literature reviewed, splenic metastasis
are rare but should be considered for patients with a his-
tory of NPC and diagnosis of splenic lesions at imaging.
There is no evidence supporting a negative impact of
splenectomy in patients with isolated splenic metastases
from NPC.
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